NATCO announces License Agreement with the Medicines Patent Pool

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has signed a non-exclusive licenses agreement with the Medicines Patent Pool (MPP), Switzerland. MPP had taken license from Merck Sharp & Dohme Corp. (MSD), USA for the same.

Natco with this license agreement can manufacture and sell molnupiravir Capsules 200 mg. for Indian market, which will be sold under brand name MOLNUNAT ® for treatment of Covid 19 infection with Sp02>93% and who have high risk of progression of the disease including hospitalization or death.

This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name. Under the license, Natco can set its own price for the generic products it produces, paying a royalty on sales to MSD. MSD, Ridgeback Biotherapeutics and Emory University will not receive royalties for sales of molnupiravir under this agreement for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 917.90 as compared to the previous close of Rs. 913.55. The total number of shares traded during the day was 6700 in over 720 trades.

The stock hit an intraday high of Rs. 920.00 and intraday low of 905.00. The net turnover during the day was Rs. 6124024.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 MedicinesPatentPool MolnupiravirCapsules